Clearant Expands Addressable Market for Orthopedic Allograft Surgeries to Include Both Soft Tissue and Bone Implants.

LOS ANGELES -- New Products Expand Product Opportunities to Markets Generating More Than $350 Million in Sales from $100 Million Previously

Clearant, Inc. (OTCBB:CLRI) today announced that it has expanded its product portfolio of allograft implants available through its direct sales force to include Clearant Process(R) sterile soft tissue implants for allograft sport medicine surgeries. Clearant now offers its sterile implants for both soft tissue and cervical spinal bone allograft surgeries through its direct distribution channel. By expanding its direct distribution initiative to include both soft and cervical spinal bone implants, Clearant has increased its addressable market from $100 million or more per year (for cervical spinal implants) to $350 million or more per year (for both soft tissue and cervical spinal implants).

Clearant's implants are sterilized using the Clearant Process, which achieves a level of sterility equal to or greater than that of medical devices while achieving excellent post-surgical clinical outcomes as compared to standard allograft tissue implants. Clearant plans to continue adding additional products later this year, including lumbar spinal bone implants, to address a market of $750 million or more per year.

"Our expanded portfolio of products will now allow us to enter lucrative markets that were previously unavailable to us," said Clearant Chief Executive Officer Alain Delongchamp. "Based on our long-standing relationships with a growing number of sports medicine surgeons and the strong positive clinical results observed with Clearant Process sterile soft tissue implants, we are confident that we will be able to accelerate the sales cycle."

"A growing number of my patients that require ligament reconstructive surgery are good candidates for allografts and are demanding safe implants. Clearant helps me better meet this rising demand with a supply of sterile implants," said Dr. Chris Larson, an orthopedic surgeon with Minnesota Sports Medicine Orthopaedic Fellowship Program and Twin Cities Orthopaedics, which has begun sourcing Clearant Sterile soft tissue implants directly from Clearant. "Based upon a growing body of clinical evidence and the results that I see first-hand in patient outcomes, Clearant's sterile implants are the best solution available today for virtually eliminating the risk of infection and ensuring high-level, post-operative performance of the tissue."

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant sterile implants(R) in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.